Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Costa LJ, Hari P, Berdeja JG, De Stefano V, Gay F, Hooper B, Bartlett M, Haltner A, Rosta E, Kumar S, Martin T, Mateos MV, Moreau P, Usmani SZ, Olyslager Y, Schecter JM, Roccia T, Garrett A, Lee S, Nesheiwat T, Pacaud L, Zhou C, Samjoo IA, Lin Y, Diels J, Valluri S, Weisel K.
Costa LJ, et al. Among authors: valluri s.
Curr Med Res Opin. 2022 Oct;38(10):1759-1767. doi: 10.1080/03007995.2022.2100651. Epub 2022 Aug 10.
Curr Med Res Opin. 2022.
PMID: 35815818